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(28.5%) had died, with median OS of 168.5  months. Although PPTIDs 
have a known potential for local recurrence and craniospinal dissemination 
(quoted as 22% and 10%, respectively in WHO 2016), our data show a 
more dismal experience with 71% recurrence and 80% dissemination at first 
recurrence. Lack of standardized therapies results in challenges in individual 
patient management.
RARE-26. WHOLE GENOME SEQUENCING OF AN OSSEOUS 
METASTASIS DURING CHECKPOINT-CONTROLLED 
INTRACRANIAL GLIOBLASTOMA REVEALS NEW INSIGHTS INTO 
POTENTIAL MECHANISMS OF IMMUNE ESCAPE
Malte Mohme1, Cecile Maire2, Simon Schliffke1, Simon Joosse1, 
Malik Alawi1, Katrin Lamszus2, and Manfred Westphal2; 1University 
Medical Center Hamburg Eppendorf, Hamburg, Germany, 2Department of 
Neurosurgery, University Medical Center Hamburg-Eppendorf, Hamburg, 
Germany
Glioblastoma (GBM) has a devastating prognosis and recent advances 
in the treatment of a variety of cancer entities, e.g. through checkpoint 
inhibition, could so far not be translated into improved outcome in newly-
diagnosed GBM. Characterizing rare cases of peripheral metastases which 
succeeded in overcoming immune control, can help to understand the 
mechanisms of immune escape. Here we describe the first reported case of 
a detailed genetic and immunological characterization of a peripheral bone 
metastasis from a GBM which was controlled intracranially by anti-PD1 
checkpoint inhibition We performed whole genome sequencing (WGS) of 
the primary- and recurrent tumor, as well as the bone metastasis. Genomic 
data was analyzed for copy number variations and mutational profiles. 
In addition, immune monitoring with flow cytometric phenotyping and 
next-generation sequencing of the peripheral T-cell repertoire was used. 
A 70-year old patient developed multiple osseous metastases in the spine, 
while his IDHwt GBM recurrence was immunologically controlled with 
checkpoint inhibition. Biopsy confirmed peripheral GBM metastases. 
Immunophenotyping reflected the effective activation of the peripheral 
T-cell response, with, however, simultaneous upregulation of regulatory 
T-cells during disease progression. WGS sequencing demonstrated a dis-
tinct molecular profile of the GBM metastasis, with amplifications in 
chromosome 3 and 9, as well as genomic loss on chromosomes 4, 10 and 
11. The peripheral metastasis was distinguished by mutations in mismatch 
repair genes, such as MSH4 and MLH1, associated with a hypermutated 
phenotype. Among the mutated genes we found potential candidates in-
volved in immune escape of circulating tumor cells. This case represents 
a unique opportunity to analyze potential mechanisms of GBM-mediated 
immune escape during immune activation with anti-PD1 checkpoint 
therapy. It highlights the fact, that although an effective, disinhibited im-
mune response can control the cranial GBM disease, hypermutated tumor 
clones can evade the tumor-specific T-cell response and disseminate to dis-
tant organs.
RARE-27. UNUSUAL CASE OF TEENAGER WITH PRIMARY SPINAL 
GERMINOMA WITH INTRACRANIAL RELAPSE POST-THERAPY
Maria Kooken, Scott Wait, Carolina Fasola, Chad Jacobsen, and 
David Gass; Atrium Health Levine Children’s, Charlotte, NC, USA
We present a case of a 14-year-old male who presented with back pain 
and difficulty walking and was found to have an intradural intramedullary 
germinoma in the thoracolumbar spine. After debulking, he was treated 
with four cycles of carboplatin and etoposide and then received local 
spinal radiotherapy (RT) to the initial area of disease with margin to 30 
Gy in 17 fractions. Six months following completion of therapy, he was 
found to have an intracranial relapse. CLINICAL IMPORTANCE: Our 
patient is the second ever Hispanic and twelfth pediatric patient reported 
with primary spinal germinoma. We reviewed 54 total cases published in 
literature over last 35 years. Twenty-one patients (39%) were treated with 
surgery followed by local spinal RT (n=12) or CSI (n=9). Twenty-eight 
patients (52%) were treated with chemotherapy in addition to surgery 
and radiation. The remaining 5 patients (9%) either had surgery alone or 
details of their treatment plan were not reported. Six of the 54 patients 
experienced disease recurrence. None of the patients treated with CSI ex-
perienced disease recurrence after CSI. Ninety-six percent of patients were 
alive at last follow up. CLINICAL OUTCOME: Our patient had his re-
lapsed disease resected and CSI to 23.4 GY in 13 fractions and focal boost 
to 21.6 Gy in 12 fractions was delivered to all sites of relapsed disease. He 
is undergoing surveillance of his tumor and there is no disease recurrence 
3  months post-CSI. CONCLUSION: Primary spinal germinomas appear 
chemo responsive and radiosensitive; however, the optimal management 
to maximize disease control and minimize side effects is not clear. When 
using local spinal RT, close surveillance with brain and spine imaging seems 
indicated as relapses anywhere in the central nervous system are possible. 
Further study is needed to determine the optimum treatment approach to 
this tumor.
RARE-28. HYPOTHALAMIC GERMINOMA AND 
NEUROSARCOIDOSIS: A TALE OF TWO PATHOLOGIES
Sushant Puri, Tibor Valy-Nagy, Nadera Sweiss, Stefania Maraka, and 
Martin Nicholas; University of Illinois at Chicago, Chicago, IL, USA
CASE 1: 30-year-old Caucasian male with a history of hereditary 
cavernomas, testicular germ cell tumor s/p orchiectomy 2017 presented 
next year with a chief complain of increasing lethargy. MRI Brain showed 
a new expansile, homogenously enhancing hypothalamic lesion causing ob-
structive dilatation of the lateral ventricles. MRI of neuraxis was not con-
cerning for leptomeningeal spread. Initial differentials included suprasellar 
germinoma vs chiasmatic hypothalamic glioma vs metastatic lesion. Biop-
sies X2 showed gliosis and granulomatous inflammation. Despite radiation 
treatment for the hypothalamic mass clinical course continued to deteri-
orate. CSF results showed RBC - 1,200; WBC - 51 with 77% lymphocytes, 
3% neutrophils, 20% monocytes. FDG-PET did not reveal evidence of 
metastatic disease. He was treated presumptively for neurosarcoidosis with 
high-dose corticosteroids and azathioprine and later transitioned to metho-
trexate and infliximab. Follow up MRI scans showed a reduction in the 
hypothalamic mass. CASE 2: A 23-year-old African American male treated 
for ADEM in 2010 presented to clinic with behavioral problems in 2017. 
Initial presentation included lethargy with imaging showing an incidental 
hypothalamic mass. Initial differentials included germinoma vs infundibular 
hypophysitis vs granulomatous process. He was treated with immuno-
therapy (corticosteroids and IVIG) with partial resolution of the growth. 
He was later diagnosed with suprasellar germinoma on biopsy subsequently 
treated with 2 cycles chemotherapy and proton beam radiotherapy in 2012. 
In 2017. to exclude tumor recurrence an LP showed elevated ACE how-
ever remainder of the clinical picture was not suggestive of neurosarcoidosis. 
DISCUSSION: Multiple case series have been described wherein hypothal-
amic germinoma mimics isolated neurosarcoidosis and vice-versa. Because 
of similar clinical picture and radiographic findings, the diagnosis is challen-
ging. ACE is a nonspecific test for neurosarcoidosis, and it can be positive in 
the setting of germinoma as well. Hence specific molecular markers may be 
helpful in the diagnosis.
RARE-29. AZD8055 ENHANCES IN VIVO EFFICACY OF AFATINIB IN 
CHORDOMAS
Tianna Zhao1, I-Mei Siu1, Tara Williamson1, Haoyu Zhang1, Chenchen Ji1, 
Peter Burger2, Lucia Cottone3, Adrienne Flanagan3, Christine Hann4, and 
Gary Gallia1; 1Department of Neurosurgery, Johns Hopkins University 
School of Medicine, Baltimore, MD, USA, 2Department of Pathology, Johns 
Hopkins University School of Medicine, Baltimore, MD, USA, 3Department 
of Pathology, University College London, Cancer Institute, London, United 
Kingdom, 4Department of Oncology, Johns Hopkins University School of 
Medicine, Baltimore, MD, USA
INTRODUCTION: Chordomas are rare, locally aggressive bone tumors 
that arise in cranial base, mobile spine, and sacrum. Currently, there are no 
FDA-approved therapies for chordoma patients, thus there is a high unmet 
need to develop effective treatments. In this study, we aim to evaluate the 
anti-tumor efficacy of small molecule inhibitors that target crucial oncogenic 
pathways in chordoma, as single agents or in combination, to identify novel 
therapies with the greatest translation potential.   METHODS: A panel of 
small molecule compounds that had exhibited in vitro efficacy against human 
chordoma cell lines or target known chordoma drivers was screened in vivo 
against patient-derived xenograft (PDX) models of chordoma, and their effi-
cacy was further evaluated using chordoma cell lines and xenograft models.  
RESULTS: The in vivo activity of compounds identified in a NIH Chemical 
Genomics Center screen utilizing chordoma cell lines, together with inhibi-
tors of c-MET and PDGFR, were evaluated in PDX models of chordoma that 
were previously described or recently established for this study. Inhibitors 
of EGFR (BIBX1382, erlotinib and afatinib), c-MET (crizotinib) or mTOR 
(AZD8055) significantly inhibited tumor growth in vivo but did not induce 
tumor regression. Co-inhibition of EGFR and c-MET using erlotinib and 
crizotinib synergistically reduced cell viability in chordoma cell lines but did 
not result in enhanced in vivo activity. Co-inhibition of EGFR and mTOR 
pathways using afatinib and AZD8055 synergistically reduced cell viability 
in chordoma cell lines. Importantly, co-inhibition of EGFR and mTOR also 
synergistically suppressed tumor growth in vivo, showing improved disease 
control.  CONCLUSION: Single inhibition of EGFR, c-MET or mTOR sup-
presses chordoma growth both in vitro and in vivo. Co-inhibition of EGFR 
and mTOR synergistically inhibits chordoma growth in a range of preclin-
ical models. The insights gained from our study provide a novel combination 
therapeutic strategy for patients with chordoma.
RARE-30. PEDIATRIC GLIOBLASTOMA IN THE POST-
TEMOZOLOMIDE ERA: OUTCOMES AND CHARACTERISTICS
Ankush Chandra1, Taemin Oh1, Harsh Wadhwa2,  
Sumedh Shah1, Nalin Gupta3, Mike McDermott1,  
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Francisco, San Francisco, CA, USA, 2UCSF Helen Diller Family 
Comprehensive Cancer Center, San Francisco, USA, 3University of 
California, San Francisco, Department of Neurological Surgery, 
Department of Pediatrics, San Francisco, CA, USA
INTRODUCTION: Glioblastoma (GBM) is the most common brain 
tumor, however, is a rare occurrence in children and is poorly character-
ized. We evaluated the characteristics and outcomes of pediatric GBM 
(pGBM).   METHODS: Retrospective analysis of pediatric (age< 18)  pa-
tients diagnosed with GBM undergoing first glioblastoma resection at our 
brain tumor center (2005- 2016).   RESULTS: From 1457 GBM patients, 
we identified twenty-four (1.65%) pGBMs (Median Age=9  years, Fe-
males=45.8%). Median overall survival (OS) was 32.1  months, while the 
median progression-free survival was 11.5 months. The commonest symp-
toms at presentation were headaches (54.2%,n=13) and motor symptoms 
(50%,n=12). Mean tumor diameter was 4.5  cm and 25% of the cohort 
underwent gross total resection (GTR) of their tumor. Univariate analysis 
revealed median OS significantly associated with tumor extent of resec-
tion (GTR=56.4  months; STR/Biopsy=13.7  months, p=0.001), age at sur-
gery (>10  years=43.9  months, < 10  years= 17.2  months, p=0.01), tumor 
size (> 4cm= 9.1  months, < 4cm=56.9  months, p=0.01),motor symptoms 
at presentation (present=14.9  months, absent=41.04  months, p=0.02) and 
infratentorial tumors (infratentorial=17.4 vs supratentorial=53.4  months, 
p=0.02). Multivariate analysis revealed GTR (HR 0.2[95% CI 0.07–0.72]; 
p=0.03), Age >10  years (HR 0.6[95% CI 0.02–0.64]; p=0.002), tumor 
>4  cm (HR 2.89[95% CI 1.88–4.11]; p=0.001) and EGFR amplification 
(HR 3.48[95% CI 0.82–17.4]; p=0.005) to be independent predictors of OS. 
Comparing patients under and over 10 years, we found that older patients 
had smaller tumors at presentation (4.9 vs 3.6 cms, p=0.03), greater rates 
of preoperative temozolomide (n=1,7.7% vs n=6, 54.5%) and bevacizumab 
(n=1,7.7% vs n=4, 36.4%) treatment, and lower rates of EGFR amplification 
(66.7% vs 11.1%) that could explain survival disparities between groups.   
CONCLUSION: Motor symptoms, larger tumors at presentation and tumor 
EGFR amplification may be indictive of poorer outcomes in pGBM. How-
ever, maximal tumor resection, aggressive chemoradiation and tumor presen-
tation at age >10 years may confer better prognosis in these patients.
RARE-31. TREATMENT OUTCOME OF CHILDREN WITH 
PLEOMORPHIC XANTHOASTROCYTOMA: RETROSPECTIVE 
ANALYSIS – A SINGLE INSTITUTION EXPERIENCE
Ossama Maher, Toba Niazi, Ziad Khatib, and John Ragheb; Nicklaus 
Children’s Hospital, Miami, FL, USA
BACKGROUND: Pleomorphic xanthoastrocytoma (PXA) and 
anaplastic pleomorphic xanthoastrocytoma (APXA) are two types of rare 
astrocytomas in pediatrics. There is limited literature reporting their out-
comes.   METHODS: A retrospective analysis of pediatric patients with 
diagnosis of PXA and APXA treated at Nicklaus Children’s Hospital was 
conducted using descriptive measures.  RESULTS: A chart review of patients 
with brain tumors from 2001 to 2019 revealed that 13 patients (median age 
6 years, range 2–17 years) were diagnosed with non-metastatic PXA (n=12) 
and APXA (n=1). Six patients (46%) were male. Clinical presentation in-
cluded seizures (n=8), headaches (n=2) cranial nerve palsies (n=2). Diag-
nostic imaging showed tumor in the temporal lobe (n=5), parietal lobe (n=2), 
temporoparietal lobe (n=2), frontal lobe (n=1), occipital lobe (n=1), others 
(n=2). BRAF V600E mutation were identified in three of five analyzed tu-
mors including PXA (n=4) and APXA (n=1). Surgical intervention consisted 
of gross total resection (n=8) and near/subtotal resection (n=5). Ten patients 
(76%) required a second surgery (median 2; range 1–4) due to local recur-
rence. The median time to recurrence was 3 years (range 6 months - 7 years). 
Three patients (23%) had malignant transformation of PXA, which occurred 
three to eight years from the initial surgery; one of them also had extensive 
spinal metastasis. Focal radiation was given to six patients (46%) due to 
multiple recurrence (n=2), malignant transformation (n=3), APXA (n=1). At 
a median follow up of 8 years (range 3 to 20 years), eight patients remain 
alive, three patients had lost to follow up, two patients died from progres-
sive disease. Long-term sequelae varied as follows; seizures (n=5), motor 
weakness (n=4), cranial nerve palsies (n=2), and learning disability (n=1).   
CONCLUSION: PXA is associated with high local recurrence rate and un-
commonly malignant transformation to APXA in pediatrics, which requires 
close follow-up due to unpredictable biological behavior of these tumors.
RARE-32. POLYMORPHOUS LOW-GRADE NEUROEPITHELIAL 
TUMOR OF THE YOUNG (PLNTY): GENETIC ANALYSIS CONFIRMS 
FREQUENT MAPK PATHWAY ACTIVATION
Cristiane Ida, Derek Johnson, Thomas Kollmeyer, DongKun Kim, 
Timothy Kaufmann, Benjamin Kipp, Robert Jenkins, and 
Caterina Giannini; Mayo Clinic, Rochester, MN, USA
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a 
recently described epileptogenic tumor characterized by oligodendroglioma-
like components, aberrant CD34 expression, and genetic MAPK pathway 
activation through alterations such as BRAF V600E mutation, and FGFR2-
KIAA1598/CTNNA3 and FGFR3-TACC3 fusions. We report the molecular 
profiling of PLNTY in 9 patients, 7 female: 2 male, median age at diag-
nosis of 16 years (range, 5–34). All tumors were supratentorial with diag-
nostic morphological features of PLNTY including oligodendroglioma-like 
areas and strong diffuse CD34 immunostaining. Four (of 9; 44%) tumors 
were positive for BRAF V600E immunostain, indicating the presence of a 
BRAF V600E mutation. The 6 cases evaluated for IDH status were nega-
tive by IDH1-R132H immunostain (n=5; 3 BRAF V600E-negative and 2 
BRAF V600E-positive) or by NGS (n=1; BRAF V600E-negative). Oncoscan 
chromosomal microarray performed in 5 BRAF V600E-negative tumors 
showed recurrent copy number changes including gain of whole chromo-
somes 5, 7, 8, 9, 12, 18, 19, 20, 21 and X, and loss of chromosomes 1, 
2, 10q, 13, 22 and Xq. The 10q losses (n=2) were highly suggestive of an 
FGFR2-KIAA1598 and of a potentially novel FGFR2 underlying fusion 
event in one case each. Custom targeted neuro-oncology DNA and RNA 
NGS panel performed in 2 cases revealed a fusion similar to fusions previ-
ously reported in pilocytic astrocytoma: one with a KIAA1549-BRAF (exon 
15-exon 9) fusion associated with a 7q34 ~785 kilobase deletion rather than 
the characteristic ~2 megabase duplication seen in pilocytic astrocytoma, 
and another with a QKI-NTRK2 (exon 6-exon 15) fusion associated with a 
9q21 ~191 kilobase duplication disrupting NTRK2. The KIAA1549-BRAF 
fusion-positive case also had a TP53 mutation with loss of whole chromo-
some 17, suggesting TP53 complete inactivation. This study confirms that 
PLNTY is a low-grade neuroepithelial tumor with frequent MAPK pathway 
activation and expands the spectrum of MAPK activating alterations ob-
served in PLNTY.
RARE-33. LEPTOMENINGEAL DISEASE IN PATIENTS WITH 
MIDLINE GLIOMAS HARBORING HISTONE H3 K27M MUTATIONS
Carlos Eduardo Silva Correia, Elena Pentsova, Andrew Lin, and 
Alexandra Miller; Memorial Sloan-Kettering Cancer Center, NY, NY, USA
INTRODUCTION: The 2016 WHO classification describes a specific 
subtype of midline gliomas harboring histone 3 (H3) K27M mutations which 
compromise 15–40% of gliomas in children and young adults. Since we 
began to perform molecular profiling at Memorial Sloan Kettering Cancer 
Center (MSKCC) we have observed an increased prevalence of leptomenin-
geal disease (LMD) in this population. However, the true incidence and the 
clinical behavior of this group has not been well-defined.  METHODS: This 
is a retrospective study of patients with H3K27M/I diffuse midline gliomas 
at MSKCC from 01/2012 to 01/2019. Mutations were identified through 
next-generation sequencing (NGS).   RESULTS: We identified 24 patients. 
Median age was 21 (6–70) and 13 were male. Thirteen tumors were in the 
thalamus, 6 in the brainstem, 4 in the spinal cord, and 1 in the pineal region. 
H3K27M mutations were detected by NGS from tumor tissue in 21 patients, 
from cerebral spinal fluid (CSF) circulating tumor DNA (ctDNA) in 2 and 
from tissue and CSF ctDNA in one. LMD was diagnosed in 17/24 (71%) pa-
tients radiographically. Of these, 8 underwent LP: CSF cytology was positive 
in 2/8 and CSF ctDNA was detected in 3/3. All patients received RT and one 
or more lines of chemotherapy. At analysis, thirteen patients remain alive. 
Median time to last follow up for all patients was 14.2 months. Median 
time from diagnosis to LMD was 13.2 months (0–45.1), with median OS of 
6.5 months (0.3–27) after diagnosis of LMD.  CONCLUSION: Our study 
showed that more than two-thirds of the patients with H3 K27M diffuse 
midline developed LMD. Neuroaxis imaging should be performed in con-
junction with CSF studies to diagnose LMD. Besides, CSF ctDNA represents 
an important tool to identify molecular profile of tumors when biopsy is not 
feasible or limited for the analysis.
RARE-34. TUMOR IMMUNITY AND EXTRACRANIAL 
METASTASES, AND MECHANISM OF PD-L1 EXPRESSION 
IN INTRACRANIAL SOLITARY FIBROUS TUMOR/
HEMANGIOPERICYTOMA
Dai Kamamoto, Kentaro Ohara, Yohei Kitamura, Kazunari Yoshida, and 
Hikaru Sasaki; Keio University School of Medicine, Tokyo, Japan
Intracranial solitary fibrous tumor (SFT) /hemangiopericytoma (HPC) 
are rare, however, these tumors are often associated with aggressive clin-
ical course with recurrence and/or extracranial metastasis. PD-1, PD-L1 
play important roles as immune-checkpoint mediators within tumor micro-
environment, and the antibodies to these molecules are now approved for 
the treatment of various kinds of cancers. Some mechanisms of activation 
of PD-L1 are reported, including cytokines or chemokines from immune 
cells in tumor microenvironment, and genetic mutations such as trans-
location, or amplification. We have investigated the expression of PD-1, 
PD-L1, and tumor infiltrating lymphocytes (TIL) in 16 cases of SFT/HPC by 
immunohistochemistry. Kaplan-Meier method and log-rank/Wilcoxon tests 
were used to analyze the relationship between their expression with overall 
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